阿托伐他汀对非酒精性脂肪性肝炎患者肝功能及炎性因子的影响  

Influence of atorvastatin on liver function and inflammatory factors of patients with non-alcoholic steatohepatitis

作　　者：徐永龙[1] 

机构地区：[1]松阳县人民医院内科,浙江丽水323400

出　　处：《中国中西医结合消化杂志》2016年第1期17-19,共3页Chinese Journal of Integrated Traditional and Western Medicine on Digestion

摘　　要：[目的]探讨阿托伐他汀对非酒精性脂肪性肝炎(NASH)患者肝功能和血清超敏C反应蛋白(hs-CRP)、白介素(IL)-6和IL-10的影响。[方法]选取NASH患者90例,随机分为对照组和观察组,每组45例。2组患者予以控制饮食、适当体育锻炼及常规内科保肝等治疗。观察组患者加用阿伐他汀片20 mg/次,1次/d,连用16周。对照组除不使用阿伐他汀片外余治疗与观察组相同。观察2组患者治疗前后肝功能指标和血清hs-CRP、IL-6和IL-10水平的变化。[结果]治疗16周后,2组患者ALT和GGT水平均较前明显下降(P<0.05或P<0.01),且观察组下降值较对照组更明显(P<0.05);同时2组血清hs-CRP、IL-6水平均较前明显下降,IL-10水平较前明显上升(P<0.05或P<0.01),且观察组变化幅度较对照组更明显(P<0.05)。[结论]阿托伐他汀辅助治疗NASH效果良好,能明显改善肝功能,并能降低hs-CRP和IL-6水平,升高抗炎性因子IL-10水平,从而纠正促炎性因子与抗炎性因子比例紊乱,抑制肝内炎症免疫性损伤达到治疗目的。[Objective]To discuss the influence of atorvastatin on liver function,serum high sensitivity C-reactive protein（hs-CRP）,interleukin-6and 10（IL-6and 10）of patients with non-alcoholic steatohepatitis（NASH）.[Methods]Ninety cases of patients with NASH,were divided into control group and observation group at random,with 45 cases of patients in each group.The patients in two groups were given diet control,suitable physical exercise,routine liver protection in department of medicine and etc.The patients in observation group were additionally given 20 mg atorvastatin tablet per time,once a day,for 16 weeks,while the patients in control group were given the same medical treatment as that in observation group except for atorvastatin tablets.The changes of liver function index,serum hs-CRP,IL-6and 10 levels of patients in two groups before and after medical treatment were observed.[Results]After 16weeks＇ medical treatment,ALTand GGT levels of patients in two groups obviously declined than before（P〈0.05 or P〈0.01）,and the declining rate of patients in observation group was much higher than that in control group（P〈0.05）.Meanwhile,serum hs-CRP and IL-6levels obviously declined than before,while the IL-10 level obviously rose than before（P〈0.05 or P〈0.01）,and the changing rate of patients in observation group was much higher than that in control group（P〈0.05）.[Conclusion]Atorvastatin has favorable curative effect on NASH as adjunctive therapy（AT）,which can obviously improve liver function,reduce as hs-CRP and IL-6level and increase IL-10 level,to adjust the disorder of percentage of proinflammatory cytokinesand anti-inflammatory factors,so as to inhibit liver inflammatory injury and realize the treatment objective.

关 键 词：非酒精性脂肪性肝炎 阿托伐他汀 肝功能 超敏C反应蛋白 白介素-6 白介素-10 

分 类 号：R575.1[医药卫生—消化系统]